FIG4 Gene
Introduction
Fig4 — Fig4 Phosphatase Homolog is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
FIG4 (FIG4 Phosphoinositide 5-Phosphatase) is a critical gene encoding a lipid phosphatase that regulates phosphoinositide signaling on endosomal and lysosomal membranes. FIG4 plays essential roles in membrane trafficking, organelle homeostasis, and cellular quality control mechanisms that are fundamental to neuronal survival. Mutations in FIG4 cause autosomal recessive Charcot-Marie-Tooth disease type 4J (CMT4J) and are implicated in familial amyotrophic lateral sclerosis (ALS), while variants contribute to [Parkinson's disease](/diseases/parkinsons-disease) (PD) risk through effects on lysosomal function and autophagy. [@chow2009]
<div class="infobox infobox-gene"> [@vaccari2011]
| Property | Value | [@zhang2018]
|----------|-------| [@hu2019]
| Gene Symbol | FIG4 | [@baird2014]
| Full Name | FIG4 Phosphoinositide 5-Phosphatase | [@itoh2022]
| Chromosomal Location | 6q21 | [@mcclure2021]
| NCBI Gene ID | 5896 | [@orhi2020]
| OMIM ID | 609390 | [@saha2019]
| Ensembl ID | ENSG00000112367 |
| UniProt ID | Q9UQF2 |
| Encoded Protein | FIG4 (559 amino acids) |
| Associated Diseases | ALS, Charcot-Marie-Tooth disease type 4J, Parkinson's Disease, neurodegeneration |
| Protein Domain | SAC1-like phosphatase domain |
| Molecular Function | PI(3,5)P2 5-phosphatase activity |
</div>
Molecular Function
FIG4 encodes a member of the SAC1-like phosphatase family that specifically dephosphorylates phosphatidylinositol-3,5-bisphosphate PI(3,5)P2 to phosphatidylinositol-3-phosphate (PI3P) [1]. This enzymatic activity is crucial for maintaining phosphoinositide balance on endosomal membranes:
- PI(3,5)P2 is a critical phosphoinositide enriched on late endosomes and lysosomes
- FIG4 catalyzes the dephosphorylation of the 5-phosphate position
- The reaction product PI3P regulates early endosome function and retrograde trafficking
- Proper PI(3,5)P2/PI3P balance is essential for endolysosomal system function
Substrate Specificity and Catalytic Mechanism
The FIG4 catalytic domain contains conserved motifs essential for phosphatase activity:
- CX5R motif in the active site (cysteine-dependent phosphatase)
- Substrate-binding pocket that recognizes the 3-phosphate group
- Specificity for the 5-phosphate of PI(3,5)P2
- Requires Mg2+ or Mn2+ as a cofactor for optimal activity
Protein-Protein Interactions
FIG4 interacts with several key proteins to execute its cellular functions:
- VAC14 - scaffolds the PI(3,5)P2 synthesis complex with FIG4 and PIKFYVE
- PIKFYVE - phosphorylates PI3P to generate PI(3,5)P2
- FYCO1 - interacts with PI3P for autophagosome-lysosome fusion
- VPS34/PIK3C3 - class III PI3K that produces PI3P
Cellular and Tissue Distribution
Brain Expression
FIG4 is widely expressed throughout the central nervous system with highest levels in:
- Cerebral [cortex](/brain-regions/cortex) (pyramidal neurons)
- [Hippocampus](/brain-regions/hippocampus) (CA1-CA3 regions, dentate gyrus)
- Cerebellum (Purkinje cells)
- Spinal cord (motor [neurons](/entities/neurons))
- Basal ganglia (striatal neurons)
- Brainstem nuclei
Peripheral Nervous System
In the peripheral nervous system, FIG4 is expressed in:
- Dorsal root ganglion neurons
- Schwann cells
- Motor endplates
- Peripheral axons
Cellular Localization
FIG4 localizes primarily to:
- Late endosomes
- Lysosomes
- Autophagosomes
- Cytoplasmic vesicles
- Nuclear envelope (minor fraction)
Disease Associations
Charcot-Marie-Tooth Disease Type 4J (CMT4J)
CMT4J (OMIM #611228) is an autosomal recessive demyelinating neuropathy caused by loss-of-function mutations in FIG4 [2][3].
Genetics:
- Recessive inheritance pattern
- Identified mutations: Q426X, R269X, L17P, I41T, Y780X
- Compound heterozygosity typically observed
- Carrier frequency estimated at 1:500 in some populations
Clinical Features:
- Early-onset progressive motor neuropathy
- Severe muscle weakness (starting in distal extremities)
- Sensory loss and decreased deep tendon reflexes
- Foot deformities (pes cavus, hammertoes)
- Demyelinating neuropathy on nerve conduction studies
- Variable age of onset (infancy to adolescence)
Pathogenesis:
- Loss of FIG4 phosphatase activity leads to PI(3,5)P2 accumulation
- Dysregulated endolysosomal trafficking
- Vacuolation and swelling of neurons and Schwann cells
- Impaired myelin maintenance
- Reduced axonal support from Schwann cells
Amyotrophic Lateral Sclerosis (ALS)
FIG4 mutations were first linked to familial ALS in 2009 [2]. While FIG4 accounts for a small percentage of ALS cases, it provides important mechanistic insights.
Genetics:
- Heterozygous missense mutations identified (I41T, L17P, E83K)
- Incomplete penetrance suggested
- Often found in combination with other ALS-associated gene variants
Molecular Mechanisms:
- Mutant FIG4 shows reduced phosphatase activity
- Impairs endolysosomal trafficking
- Leads to cytoplasmic vacuolization in motor neurons
- Disrupts autophagy-lysosome pathway
- Causes mitochondrial dysfunction
- Accelerates stress granule formation
Cellular Consequences:
- Accumulation of damaged organelles
- Impaired protein quality control
- Reduced clearance of aggregate-prone proteins
- Increased oxidative stress
- Calcium dysregulation
Parkinson's Disease (PD)
Emerging evidence suggests FIG4 variants may modify PD risk [4][5].
Evidence:
- FIG4 expression is reduced in PD substantia nigra
- PI(3,5)P2 pathway intersects with lysosomal function
- FIG4 deficiency impairs [alpha-synuclein](/proteins/alpha-synuclein) clearance
- GWAS nominal associations with PD risk
Mechanistic Links:
- Lysosomal dysfunction in PD pathogenesis
- Impaired autophagic clearance of alpha-synuclein
- Mitochondrial quality control defects
- Endolysosomal trafficking abnormalities
Animal Models
FIG4-Null Mice (fig4-/-, fig4tm1.1Kyan)
Mice lacking FIG4 exhibit severe neurological phenotypes:
- Neonatal lethality (most die within 2 days)
- Severe vacuolization in brain and peripheral nerves
- Accumulation of swollen endosomes/lysosomes
- Tremor and movement defects
- Hypotonia
FIG4 Conditional Knockout
Neuron-specific deletion demonstrates:
- Progressive neurodegeneration
- Motor coordination deficits
- Age-dependent phenotype progression
- Vacuolation in neurons
- [Autophagy](/entities/autophagy) impairment
Transgenic Models
Mouse models expressing human FIG4 mutations:
- I41T: vacuolation, motor neuron degeneration
- L17P: partial loss of function phenotype
- Rescue experiments with wild-type FIG4
Zebrafish Models
Zebrafish fig4 morphants show:
- Developmental abnormalities
- Motor neuron pathfinding defects
- Vacuole formation
- Useful for drug screening
Therapeutic Implications
Gene Therapy Approaches
- AAV-mediated FIG4 delivery to CNS
- Targeted expression to motor neurons
- Promising in mouse models
- Challenges: delivery efficiency, dosing
Small Molecule Modulators
Phosphoinositide Modulators:
- PI(3,5)P2 analogs or precursors
- PIKFYVE inhibitors (to reduce PI(3,5)P2 accumulation)
- [mTOR](/mechanisms/mtor-signaling-pathway) inhibitors (to enhance autophagy)
Repurposed Drugs:
- Amiloride (enhances macroautophagy)
- Rapamycin (mTOR inhibition)
- Sodium butyrate ([HDAC](/entities/hdac-enzymes) inhibition)
Protein Replacement Therapy
- Recombinant FIG4 protein delivery
- [Blood-brain barrier](/entities/blood-brain-barrier) penetration challenges
- Enzyme replacement considerations
Neuroprotective Strategies
- Supportive therapies for CMT4J
- Physical therapy and rehabilitation
- Assistive devices for mobility
- Pain management
Diagnostic Testing
Genetic Testing
- Clinical sequencing of FIG4 coding exons
- Deletion/duplication analysis
- Panel testing for inherited neuropathies
- Preimplantation genetic diagnosis available
Biomarkers
- Elevated CSF phosphoinositides (research)
- Skin biopsy showing vacuolization
- Nerve conduction studies
- MRI for CNS involvement
Research Directions
Current Research Areas
Structure-Function Studies
- Crystal structure of FIG4 catalytic domain
- Mutation impact on enzymatic activity
- Interaction interface mapping
Therapeutic Development
- AAV gene therapy optimization
- Small molecule screening
- Drug repurposing screens
Disease Mechanisms
- Endolysosomal trafficking defects
- Autophagy-lysosome pathway
- Mitochondrial interactions
Biomarkers
- Disease progression markers
- Treatment response indicators
- Early detection methods
Clinical Trials
Currently, no FIG4-specific clinical trials are recruiting. However, trials for related neuropathies and ALS may include FIG4 patients:
- NCT05318798: Natural History Study of CMT and Related Neuropathies
- NCT05645614: Gene Therapy for Monogenic Neuropathies
See Also
- [/diseases/als](/diseases/amyotrophic-lateral-sclerosis) - Amyotrophic Lateral Sclerosis
- [/diseases/parkinsons-disease](/diseases/parkinsons-disease) - Parkinson's Disease
- [/diseases/charcot-marie-tooth-disease](/diseases/charcot-marie-tooth-disease) - Charcot-Marie-Tooth Disease
- [/proteins/fig4-protein](/proteins/fig4-protein) - FIG4 Protein
- [/mechanisms/lysosomal-function](/mechanisms/lysosomal-dysfunction)) - Lysosomal Function
- [/mechanisms/autophagy](/mechanisms/autophagy) - Autophagy in Neurodegeneration
- [/mechanisms/mitochondrial-dysfunction](/mechanisms/mitochondrial-dysfunction) - Mitochondrial Dysfunction
Background
The study of Fig4 — Fig4 Phosphatase Homolog has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
Brain Atlas Resources
- [Allen Human Brain Atlas - FIG4 Expression](https://human.brain-map.org/microarray/search/show?search_term=FIG4): Gene expression data across brain regions
- [Allen Cell Type Atlas](https://celltypes.brain-map.org/): Cellular expression patterns in neurons and glia
- [BrainSpan - FIG4 Developmental Expression](https://brainspan.org/): Developmental transcriptome data
- [Allen Mouse Brain Atlas](https://mouse.brain-map.org/): Mouse brain expression data
References
[Zhang et al., PI(3,5)P2 metabolism in neurodegenerative disease (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32847625/)
[Chow et al., FIG4 mutations in ALS and CMT4J (2009) (2009)](https://doi.org/10.1038/ng.443)
[Vaccari et al., FIG4 deficiency in CMT4J (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21820108/)
[Zhang et al., FIG4 variants in Parkinson's disease (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29649707/)
[Hu et al., Lysosomal dysfunction in FIG4 deficiency (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31112345/)
[Baird et al., FIG4 and phosphoinositide signaling (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24485052/)
[Itoh et al., FIG4 in autophagy (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35653612/)
[McClure et al., AAV gene therapy for FIG4 deficiency (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34011025/)
[Orhi et al., CMT4J natural history (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32098590/)
[Saha et al., Endolysosomal trafficking in neurodegeneration (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31619826/)Pathway Diagram
The following diagram shows the key molecular relationships involving FIG4 — FIG4 Phosphatase Homolog discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)